Centre for Pharmaceutical Studies (CEF), Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal,
Eur J Clin Microbiol Infect Dis. 2013 Oct;32(10):1231-52. doi: 10.1007/s10096-013-1876-y. Epub 2013 Apr 26.
Cystic fibrosis (CF) is a complex inherited disease which affects many organs, including the pancreas and liver, gastrointestinal tract and reproductive system, sweat glands and, particularly, the respiratory system. Pseudomonas aeruginosa is the main cause of chronic airway infection. In order to reduce morbidity and mortality due to lung infection by P. aeruginosa, aerosol antibiotics have been used to achieve high local concentrations in the airways and to reduce systemic toxicity. In the course of this review, the current treatments to control CF lung infections by P. aeruginosa are presented. Some innovative aerosol formulations such as liposomes and microspheres are herein reviewed, which may improve the efficiency of anti-pseudomonal agents, and ensure patients' compliance to treatments, by reducing dosing frequency and/or drug dose, while maintaining therapeutic efficacy, preventing the occurrence of bacterial resistance and/or reducing adverse effects due to their controlled-release properties.
囊性纤维化（CF）是一种复杂的遗传性疾病，影响多个器官，包括胰腺和肝脏、胃肠道和生殖系统、汗腺，特别是呼吸系统。铜绿假单胞菌是慢性气道感染的主要原因。为了降低铜绿假单胞菌肺部感染导致的发病率和死亡率，已使用气溶胶抗生素在气道中达到高局部浓度，以降低全身毒性。在本综述过程中，介绍了目前控制 CF 肺部铜绿假单胞菌感染的治疗方法。本文还回顾了一些创新的气溶胶制剂，如脂质体和微球，它们可以通过减少给药频率和/或药物剂量，同时保持治疗效果、防止细菌耐药性的产生和/或减少由于其控释特性而产生的不良反应，来提高抗假单胞菌药物的效率，并确保患者对治疗的依从性。
